Anthracycline Toxicity: Light at the End of the Tunnel?

Area of Science:

• Genetics and Genomics
• Cardiology
• Pharmacology

Background:

• Anthracycline-induced cardiotoxicity (AIC) is a significant clinical challenge in cancer therapy.
• Identifying genetic factors influencing AIC risk is crucial for personalized medicine.
• Current understanding of AIC-associated genes requires further mechanistic and functional elucidation.

Purpose of the Study:

• To review known genes associated with AIC and their mechanistic roles.
• To highlight the importance of functional validation of genetic variants using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).
• To explore the potential of patient-specific hiPSC-CMs for novel target identification and cardioprotectant drug discovery.

Main Methods:

• Comprehensive literature review of association studies identifying AIC-related genes.
• Categorization of genes based on their mechanistic implications in AIC.
• Discussion on the utility of functional validation in hiPSC-CMs for genetic biomarker development.

Main Results:

• Overview of established AIC genes and their functional pathways.
• Emphasis on the critical role of hiPSC-CMs in validating genetic variants.
• Potential for patient-specific hiPSC-CMs in discovering novel cardioprotective strategies.

Conclusions:

• Functional validation of AIC-associated variants in hiPSC-CMs is essential for clinical biomarker implementation.
• Patient-specific hiPSC-CMs offer a powerful platform for personalized cardioprotectant drug discovery.
• This approach will accelerate the development of next-generation AIC prevention strategies and personalized therapies.